Results 11 to 20 of about 207,130 (329)
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. [PDF]
Journal of Cancer, 2016 Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein.
Burke, Amos +13 more
core +10 more sources
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]
, 2017 Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht +6 more
core +3 more sources
ALK and NSCLC: Targeted therapy with ALK inhibitors [PDF]
F1000 Medicine Reports, 2011 For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes over recent years.
Hallberg, Bengt, Palmer, Ruth H.
openaire +2 more sources
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. [PDF]
, 2017 Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved
Bivona, Trever G +2 more
core +3 more sources
Allergology International, 2018 Allergy immunotherapy (AIT) is a treatment option for respiratory allergy that is complementary to pharmacotherapy, with a distinct mechanism of action.
Hendrik Nolte, Jennifer Maloney
doaj +1 more source
Silenced Expression of NFKBIA in Lung Adenocarcinoma Patients with a Never-smoking History [PDF]
, 2013 Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas.
Asano, Hiroaki +12 more
core +1 more source
Successful role of adjuvant radiotherapy in a rare case of tracheal inflammatory myofibroblastic tumor: a case report [PDF]
, 2019 BACKGROUND:: Inflammatory myofibroblastic tumor (IMT) is a rare benign cancer that can express a more aggressive phenotype related to the genetic mutation of the anaplastic lymphoma kinase receptor (ALK). Involvement of trachea is extremely rare and due
Abate, Gessica +7 more
core +1 more source
Allergy, Asthma & Clinical Immunology, 2018 Background The prevalence of adverse food reactions in patients with chronic inhalant diseases has seldom been studied in China. This study is to investigate the prevalence of adverse food reactions and the symptoms caused in respiratory patients ...
Guodong Hao +7 more
doaj +1 more source
ALK Inhibitors in the Treatment of ALK Positive NSCLC [PDF]
Frontiers in Oncology, 2019 Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have assembled the evidence related to the efficacy and safety of these agents in the treatment of ALK positive NSCLC ...
Muhammad Khan +10 more
openaire +3 more sources